NCT02384499View on ClinicalTrials.gov

Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Fecal Incontinence
Interventions
BIOLOGICAL

ALLO-ASC injection

Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence

DRUG

Placebo

0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence

Trial Locations (1)

135-720

Section of Colon and Rectal Surger, Department of Surgery, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02384499 - Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study | Biotech Hunter | Biotech Hunter